Guosong Liu, MD, PhD – Chief Executive Officer / Founder
Dr. Liu received his PhD in Physiological Sciences from the University of California, Los Angeles in 1990. He completed post-doctoral scientific training at Stanford University and held faculty positions at Picower Institute of Learning and Memory at Massachusetts Institute of Technology and at Tsinghua University.
Dr. Liu is a world-renowned expert in synaptic physiology, learning, memory, and emotional control. His research focuses primarily on the principles of synaptic density regulation in the brain under physiological and pathological conditions. His discoveries underlie strategies for designing drug candidates against novel targets for treating synaptic dysfunction, neurodegeneration and brain atrophy.
He founded Neurocentria based on these discoveries to develop treatments for cognitive impairment and other neurodegenerative diseases. Neurocentria’s leading drug candidate shows promising results for treating age- and dementia-related cognitive decline in elderly and early AD patients, and is currently in late-stage clinical development. Dr. Liu is the CEO of Neurocentria and oversees its multiple clinical development programs.
Fei Mao, PhD – Chief Chemist / Founder
Dr. Mao, received his PhD in Chemistry from the University of Oregon in 1990. Dr. Mao is a prolific inventor with more than 100 U.S. patents and more than 100 pending U.S. patents. He is also the founder of Biotium, Inc., a world leader in fluorescent molecular reagents – essential tools for biomedical research. Dr. Mao’s fluorescent dyes and probes are widely used for life science research, medical diagnostics, and drug screening, and in particular are useful for determining synaptic density and function. Among his most important inventions is FM1-43, a fluorescent probe co-developed with Professor William J. Betz of the University of Colorado for tracking synaptic transmission in living neurons. FM1-43 was a critical imaging tool used in Dr. Liu’s lab for discovering how synaptic function is regulated, establishing the foundation for Neurocentria’s candidate drug, MMFS.